MD Anderson study finds weekly dose reduces a targeted drug's side effects but not its activity against acute lymphocytic leukemia
A potent chemotherapy agent wrapped within a monoclonal antibody selectively destroys the malignant cells responsible for acute lymphocytic leukemia (ALL) in either weekly or monthly dosing, researchers report at the 54th ASH Annual Meeting and Exposition. This "Trojan horse" assault on the cancer cells has significantly increased the response rate among patients with ALL, and now an MD Anderson Cancer Center clinical trial finds that weekly dosing works well and reduces side effects.
Among the research institutions NCI funds across the United States, it currently designates 67 as Cancer Centers. Largely based in research universities, these facilities are home to many of the NCI-supported scientists who conduct a wide range of intense, laboratory research into cancer’s origins and development. The Cancer Centers Program also focuses on trans-disciplinary research, including population science and clinical research. The centers’ research results are often at the forefront of studies in the cancer field.